Prolacta Bioscience
48 articles about Prolacta Bioscience
-
Hot Topics in Neonatology® 2022 Conference Will Include Symposium on Benefits of Vat Pasteurization for Human Donor Milk
12/5/2022
Prolacta Bioscience® announced that Dr. David Dallas, PhD, of Oregon State University will present published data on the effects of various manufacturing methods on bioactive proteins in donor human milk at the Hot Topics in Neonatology® 2022 conference in National Harbor, Maryland, on Tuesday, Dec. 6, at 12:15 p.m.
-
New Study Finds Improved Long-Term Neurodevelopmental Outcomes for Extremely Premature Infants Fed Prolacta's Exclusive Human Milk Diet (EHMD)
11/9/2022
Prolacta Bioscience® announced the publication of a journal article that showed improved long-term neurodevelopmental outcomes in extremely premature infants who received Prolacta's 100% human milk-based fortifiers as part of an Exclusive Human Milk Diet, compared with infants fed a cow milk-based diet in the neonatal intensive care unit.
-
Prolacta Bioscience Celebrated Breastfeeding Awareness Month by Recognizing the Commitment of NICU Parents to Their Infants' Health
8/29/2022
Prolacta Bioscience ®, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, celebrated Breastfeeding Awareness Month by recognizing the commitment of NICU parents to their infants' health through advocating for and/or providing essential human milk nutrition.
-
In a first, Prolacta Bioscience recently published a proof of concept study showing that components of human breast milk can treat the adult microbiome without antibiotics.
-
Prolacta Bioscience Appoints Dr. Erin Hamilton Spence as Director of Clinical Education and Professional Development
8/2/2022
Prolacta Bioscience®, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, announced today that neonatologist and breastfeeding advocate Erin Hamilton Spence, MD, IBCLC, has been appointed director of clinical education and professional development.
-
Multiple Peer-Reviewed Studies Show Prolacta's 100% Human Milk-Based Nutritional Fortifiers Reduce Risk of Life-Threatening Comorbidities in Premature Infants, Compared to Cow Milk-Based Nutrition
7/27/2022
Prolacta Bioscience®, reports that data from a growing body of peer-reviewed clinical studies show a reduced risk of several comorbidities among premature infants who received Prolacta's 100% human milk-based fortifiers as part of Exclusive Human Milk Diet (Prolacta's EHMD), compared to premature infants fed cow milk-based fortifiers.
-
Prolacta Bioscience Introduces Its First Evidence-Based Feeding Protocol for an Exclusive Human Milk Diet in the NICU
6/14/2022
Prolacta Bioscience® announced the introduction of the first evidence-based feeding protocol for the use of an Exclusive Human Milk Diet including Prolacta's products in the neonatal intensive care unit.
-
Prolacta Bioscience Enrolls First Infant in Japan-based Clinical Trial to Evaluate the Effect of an Exclusive Human Milk Diet on Growth and Safety in Premature Infants
12/1/2021
Company Meets PMDA Stringent Quality Standards; Continues Efforts to Serve More Premature Infants Throughout the World.
-
Prolacta Bioscience's Mindy Fuzesy Presents at Association of Women's Health, Obstetric and Neonatal Nurses 2021 Virtual Convention
10/11/2021
Prolacta Bioscience announced that Mindy Fuzesy, RNC-NIC, RNC-OB, MSL-BC presented at the Association of Women's Health, Obstetric and Neonatal Nurses (AWHONN) virtual convention on Sunday, October 10, at 4 p.m. ET.
-
Prolacta Bioscience Congratulates Carolyn TenEyck, RN, on Lifetime Achievement Award from National Black Nurses Association
8/10/2021
Prolacta Bioscience is proud to announce the company's senior director of advocacy and government affairs, Carolyn TenEyck, RN, was honored with the Lifetime Achievement Award from the National Black Nurses Association (NBNA) for her remarkable contributions to improving the lives of numerous patient groups over the last 20 years, including premature and critically ill infants.
-
Late-Onset Sepsis Reduced in Premature Infants Fed Prolacta's 100% Human Milk-Based Fortifiers as Part of an Exclusive Human Milk Diet
12/9/2020
Studies Showed Hospitals Effectively Reduced Both the Incidence of and Evaluations for Late-Onset Sepsis When Prolacta's Fortifiers Were Used in Lieu of Cow Milk-Based Fortifiers
-
Enrollment Passes Halfway Milestone in Clinical Trial Evaluating the Effect of an Exclusive Human Milk Diet Including a Specialty Fortifier in Term Infants Born with Single Ventricle Congenital Heart Defects
8/9/2018
Prolacta Bioscience® announced that enrollment has passed the halfway milestone in a randomized controlled study evaluating how growth and clinical outcomes are affected when an exclusive human milk diet (EHMD)1 including a specialty fortifier is provided in the immediate post-surgical period to term infants who have undergone surgery to address a serious heart defect known as single ventricle cardiac physiology.
-
New Analysis Published in the Journal Breastfeeding Medicine Finds Additional Clinically Significant Benefits From an Exclusive Human Milk Diet in the NICU
7/25/2018
A Greater Volume of Cow Milk-Based Nutrition Correlates With More Days of Interventions for Extremely Premature Infants
-
Starting 100 Percent Human Milk-Based Fortifier Early Is Associated With Improved Growth in Extremely Premature Infants, According to an Independent Study
7/9/2018
Infants Showed Improved Gains in Weight, Length and Head Circumference
-
Prolacta Bioscience® to Present at the Cowen and Company 38th Annual Health Care Conference on March 14, 2018
3/8/2018
Prolacta Bioscience, the nation's leading provider of human milk-based neonatal nutritional products to hospitals, announced today that it will present at the Cowen and Company 38th Annual Health Care Conference in Boston, MA. Scott Elster, Prolacta's President and Chief Executive Officer, is scheduled to present on Wednesday, March 14, 2018, at 2:30 PM EDT.
-
Prolacta Bioscience Launches New Resources For Nurses, Clinicians Working With Premature Infants
8/18/2017
-
Prolacta Bioscience Applauds The National Black Nurses Association Safe Human Donor Milk Resolution Calling For Higher Donor Milk Safety And Screening Standards
8/18/2017
-
Prolacta Bioscience Applauds New York Gov. Cuomo, Assemblywoman Solages, Senator Hannon & State Lawmakers For Providing Access To An Exclusive Human Milk Diet For Extremely Premature Infants
5/16/2017
-
Prolacta Bioscience Names New Nutrition Advisory Committee Members And Expands Resources For NICU Dietitians And Clinicians
3/31/2017
-
Prolacta Bioscience To Present At The 2017 RBC Capital Markets Healthcare Conference On February 22, 2017
2/22/2017